“Transdiagnostic” clusters

 

“In current models of neurodegeneration, individual diseases are defined by the presence of one or two pathogenic protein species. Yet, it is the rule rather than the exception that a patient meets criteria for more than one disease”

These are the first lines of a manuscript on the preprint sharing webiste BioRxiv, which analysed the co-occurance of biological markers of Alzheimer’s or Parkinson’s or other neurodegenerative conditions across 18 brain regions in 1389 postmortem brain from people who passed away with a neurodegenerative condition.

The results are interesting.

In today’s post, we will discuss what this study did, what is meant by “transdiagnostic disease clusters”, and consider what could they mean for our understanding of Parkinson’s… and heck, neurodegenerative conditions in general.

 


Malcolm Gladwell. Source: Masterclass

I am a fan of Malcolm Gadwell (not an endorsement, this is just me sharing).

He has a great way of looking at a situation from a completely different angle, finding things that no one else sees, and then writing about it in a clever, easy to read manner. Having read most of his books, I was rather pleased to learn that he has a podcast – Revisionist History.

And it’s good.

Oh boy, it’s good.

The first episodes of the most recent series of the podcast have helped to raise my fragile self esteem, because I am definitely a tortoise (just listen to the first two episodes of season 4 and you’ll understand).

Oh, and Mr Gladwell, if you ever read this – in the next series of the podcast, please have a look at the dysfunctional way we clinically test new therapies in medicine – click here to read a previous SoPD rant on this topic. Thanks!

What does Malcolm Gladwell have to do with Parkinson’s?

It all comes back to that idea of looking at a situation from a completely different angle.

What do you mean?

Continue reading ““Transdiagnostic” clusters”

Guten tag! MODAG

 

Last week the German biotech firm MODAG announced that they had secure €12M in series A funding from various venture capital investors.

The company is going to use those funds to clinically develop their lead compound – Anle138b – in the neurodegenerative condition, Multiple Systems Atrophy (or MSA). 

In today’s post, we will discuss how Anle138b works, what Multiple Systems Atrophy is, and how this news could be good for the Parkinson’s community.

 


Stealth mode. Source: Hackernoon

Last week a small biotech firm in Germany came out of ‘stealth mode’.

What is stealth mode?

According to wikipedia, “in business, stealth mode is a company’s temporary state of secretiveness, usually undertaken to avoid alerting competitors to a pending product launch or other business initiative”.

After years of developing a novel drug, the German company emerged from stealth mode with €12M in series A funding, which will be used to clinically test their new treatment.

The company’s name is MODAG.

And what is MODAG planning to do now they are out of “stealth mode”?

They are planning to clinically test their lead compound which is called Anle138b.

The initial Phase I safety test will be conducted in healthy individuals, but then they will turn their attention to individuals with multiple systems atrophy.

What is Multiple System Atrophy?

Continue reading “Guten tag! MODAG”